EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Breast Milk Excretion of Dinalbuphine Sebacate Injection Administered After Cesarean Section

Sung-Ling Tang, Kai-Yi Wang, Wen-Kai Hsiao, Chi-Kang Lin

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.2416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Sung-Ling Tang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Nalbuphine, Milk, Human, Cesarean Section, Postoperative Pain. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ensuring the safety of analgesics during lactation is crucial for women of childbearing potential. Available data regarding the transfer of nalbuphine for postoperative acute pain via breast milk are limited to the postmarketing experience. This lactation study aimed to assess nalbuphine and dinalbuphine sebacate concentrations in breast milk from lactating women with postoperative pain treated with dinalbuphine sebacate extended‐release injection (150 mg dinalbuphine sebacate/2 mL Naldebain). Breast milk was collected throughout the 5‐day posthospitalization interval from 20 mothers injected with one dose of extended‐release dinalbuphine sebacate intramuscularly. Maternal safety was assessed during the study period. Nalbuphine was detectable in 71% of milk samples collected from all mothers, whereas dinalbuphine sebacate was undetectable or below the quantitation limit (0.1 ng/mL). The mean nalbuphine concentration in milk was approximately 10.55 ng/mL, with the peak concentration reaching up to 12.7 ng/mL. The mean relative infant dose was 0.39% (coefficient of variation, 65%). The mean pain intensity at rest was reduced to mild pain from Day 2 morning to discharge. Overall, the maternal safety profile was tolerable. The breast milk of women who receive one dose of dinalbuphine sebacate injection postpartum contains low nalbuphine concentration. In addition, dinalbuphine sebacate injection potentially reduces maternal pain intensity during the first postpartum week and offers low toxicity risk among breastfed infants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NalbuphineMilk, HumanCesarean SectionPostoperative PainAnalgesics, OpioidHumansFemaleAdultInjections, IntramuscularLactationPregnancyYoung Adult

Stichwörter der Autor:innen

breastfeedcesarean sectionmultimodal analgesianalbuphinerelative infant dose

Substanzen

NalbuphineAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan.
  • School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
  • Lumosa Therapeutics, Taipei, Taiwan.
  • Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

Zitieren

APA

Tang, S. L., Wang, K. Y., Hsiao, W. K., & Lin, C. K. (2024). Breast Milk Excretion of Dinalbuphine Sebacate Injection Administered After Cesarean Section. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2416

Vancouver

Tang SL, Wang KY, Hsiao WK, Lin CK. Breast Milk Excretion of Dinalbuphine Sebacate Injection Administered After Cesarean Section. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2416

BibTeX
@article{Tang2024,
  author = {Tang, Sung-Ling and Wang, Kai-Yi and Hsiao, Wen-Kai and Lin, Chi-Kang},
  title = {Breast Milk Excretion of Dinalbuphine Sebacate Injection Administered After Cesarean Section},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.2416}
}
Kostenlos starten →